Insider Transactions in Q2 2021 at Quanterix Corp (QTRX)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 23
2021
|
David C. Duffy SVP R&D and CTO |
SELL
Open market or private sale
|
Direct |
1,667
-4.77%
|
$103,354
$62.11 P/Share
|
|
Jun 15
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
696
-1.85%
|
$44,544
$64.33 P/Share
|
|
Jun 14
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.26%
|
$330,000
$66.62 P/Share
|
|
Jun 09
2021
|
Masoud Toloue President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
50,703
+50.0%
|
-
|
|
Jun 07
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
13,549
-14.26%
|
$799,391
$59.5 P/Share
|
|
Jun 07
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
BUY
Exercise of conversion of derivative security
|
Direct |
18,396
+9.32%
|
$404,712
$22.93 P/Share
|
|
Jun 07
2021
|
Marijn E Dekkers |
SELL
Open market or private sale
|
Direct |
9,051
-52.95%
|
$497,805
$55.91 P/Share
|
|
Jun 07
2021
|
Marijn E Dekkers |
BUY
Exercise of conversion of derivative security
|
Direct |
4,732
+29.48%
|
$108,836
$23.12 P/Share
|
|
Jun 04
2021
|
Marijn E Dekkers |
SELL
Open market or private sale
|
Direct |
7,610
-53.6%
|
$418,550
$55.05 P/Share
|
|
Jun 04
2021
|
Marijn E Dekkers |
BUY
Exercise of conversion of derivative security
|
Direct |
5,119
+16.64%
|
$76,785
$15.64 P/Share
|
|
Jun 02
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.26%
|
$245,000
$49.22 P/Share
|
|
Jun 01
2021
|
John J Fry General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
226
-0.65%
|
$10,848
$48.32 P/Share
|
|
Jun 01
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
243
-0.74%
|
$11,664
$48.32 P/Share
|
|
Jun 01
2021
|
Mark T. Roskey SVP, Strategic Partnerships |
SELL
Open market or private sale
|
Direct |
153
-0.63%
|
$7,344
$48.32 P/Share
|
|
Jun 01
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
3,854
-0.4%
|
$184,992
$48.32 P/Share
|
|
May 28
2021
|
David C. Duffy SVP R&D and CTO |
SELL
Open market or private sale
|
Direct |
1,667
-4.55%
|
$85,017
$51.0 P/Share
|
|
May 25
2021
|
Keith Crandell |
BUY
Other acquisition or disposition
|
Direct |
11,236
+12.93%
|
-
|
|
May 25
2021
|
Keith Crandell |
SELL
Other acquisition or disposition
|
Indirect |
350,000
-22.29%
|
-
|
|
May 19
2021
|
Keith Crandell |
BUY
Other acquisition or disposition
|
Direct |
11,237
+14.86%
|
-
|
|
May 19
2021
|
Keith Crandell |
SELL
Other acquisition or disposition
|
Indirect |
350,000
-18.23%
|
-
|
|
May 13
2021
|
Keith Crandell |
BUY
Other acquisition or disposition
|
Direct |
11,237
+17.45%
|
-
|
|
May 13
2021
|
Keith Crandell |
SELL
Other acquisition or disposition
|
Indirect |
350,000
-15.42%
|
-
|
|
May 13
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.17%
|
$230,000
$46.38 P/Share
|
|
May 11
2021
|
Shawn Stetson Interim CFO and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
1,423
+23.19%
|
-
|
|
May 03
2021
|
Amol Chaubal Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
178
-0.15%
|
$10,324
$58.95 P/Share
|
|
May 03
2021
|
John J Fry General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
217
-0.16%
|
$12,586
$58.95 P/Share
|
|
May 03
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
234
-0.18%
|
$13,572
$58.95 P/Share
|
|
May 03
2021
|
Mark T. Roskey SVP, Strategic Partnerships |
SELL
Open market or private sale
|
Direct |
147
-0.15%
|
$8,526
$58.95 P/Share
|
|
May 03
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
5,789
-0.07%
|
$341,551
$59.17 P/Share
|
|
Apr 27
2021
|
Laurie J Olson |
BUY
Grant, award, or other acquisition
|
Direct |
4,540
+50.0%
|
-
|
|
Apr 20
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.26%
|
$290,000
$58.26 P/Share
|
|
Apr 15
2021
|
David C. Duffy SVP R&D and CTO |
SELL
Open market or private sale
|
Direct |
1,667
-4.35%
|
$103,354
$62.14 P/Share
|
|
Apr 08
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.25%
|
$325,000
$65.38 P/Share
|
|
Apr 01
2021
|
Amol Chaubal Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
165
-0.18%
|
$10,230
$62.66 P/Share
|
|
Apr 01
2021
|
John J Fry General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
201
-0.19%
|
$12,462
$62.66 P/Share
|
|
Apr 01
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
3,432
-0.12%
|
$212,784
$62.66 P/Share
|
|
Apr 01
2021
|
Mark T. Roskey SVP, Strategic Partnerships |
SELL
Open market or private sale
|
Direct |
136
-0.18%
|
$8,432
$62.66 P/Share
|
|
Apr 01
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
215
-0.21%
|
$13,330
$62.66 P/Share
|
|
Apr 01
2021
|
Keith Crandell |
BUY
Grant, award, or other acquisition
|
Direct |
211
+1.42%
|
$12,871
$61.45 P/Share
|
|
Apr 01
2021
|
Sarah E. Hlavinka |
BUY
Grant, award, or other acquisition
|
Direct |
193
+1.66%
|
$11,773
$61.45 P/Share
|
|
Apr 01
2021
|
Martin D Madaus |
BUY
Grant, award, or other acquisition
|
Direct |
294
+1.96%
|
$17,934
$61.45 P/Share
|
|
Apr 01
2021
|
Paul M Meister |
BUY
Grant, award, or other acquisition
|
Direct |
223
+1.63%
|
$13,603
$61.45 P/Share
|